TikoMed presents IBsolvMIR at BIO Europe
Written on 2018-03-22
IBsolvMIR is TikoMeds original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that occurs when transplanted cells enter the bloodstream and come in contact with blood. IBsolvMIR has been documented to be a very safe drug and has shown efficacy in a Phase 2 study. TikoMed will now focus efforts on partnering strategy in order to bring the drug to the market.
At BIO Europe, Adam Bruce, founder of TikoMed presented development status and partner strategy for the project.